Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Hosted on MSN1d
LLY Falls Around 14% in 3 Months: How to Play the StockEli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...
According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...
If you’re taking tirzepatide for weight loss, you might find the drug isn’t covered by insurance. It comes with a hefty price tag, which can add up if you take the drug for a long time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback